Dr. Anh Wartel earned her MD at the Paris XII Medical School, France, and completed a post-graduate diploma in Public Health from the University of Liverpool, UK. She is an honorary Professor at the University of Rwanda.
Anh Wartel, M.D., is the Deputy Director General, Regional Director of the IVI Europe
Regional Office, overseeing IVI’s operational, scientific, and technical activities in the Europe region, including the Europe Regional Office in Stockholm and a Country Office in Vienna. She is based in Stockholm, Sweden.
Dr. Wartel joined IVI in 2018 as the Head of Clinical Development and Regulatory, then the Deputy Director General of the Clinical, Assessment, Regulatory, Evaluation (CARE) unit. She has twenty-five years of experience in clinical research.
Before IVI, Dr. Wartel held various positions in epidemiology, clinical R&D, and medical affairs, overseeing multiple clinical developments (e.g., rabies, cholera, typhoid fever, hepatitis A, yellow fever, dengue, Japanese encephalitis vaccines) in pre- and post-licensure stages at Sanofi in Asia for 15 years. She initially started her research career with the French National Agency of Research on HIV/AIDS (ANRS), involved in drug trial projects as an investigator for five years in Paris.
Professor Padmashree Gehl Sampath is an experienced academician and leading figure in the field of development studies and global health. She holds a Ph.D. from the University of Hamburg, Germany. Her extensive work spans 3 sectors namely; pharmaceuticals and health, digital economy, energy and climate change.
Jerome H. Kim, M.D., is the Director General of IVI and an international expert on the development and evaluation of vaccines. Jerome H. Kim, M.D., is the Director General of IVI and an international expert on the development and evaluation of vaccines.
Prior to IVI, he served as the Principal Deputy, US Military HIV Research Program and the Chief, Laboratory of Molecular Virology and Pathogenesis at the Walter Reed Army Institute of Research; and the US Army Program Manager for HIV vaccines. He led the Army’s RV144 Phase III HIV vaccine trial that showed efficacy in the prevention of HIV-1.
Dr. Kim is an Adjunct Professor, Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, USA; Adjunct Professor, Graduate School of Public Health, Yonsei University, Republic of Korea; and an Honorary Professor, University of Rwanda. He was also named a Distinguished Visiting Professor, Seoul National University in 2022. He has authored over 350 publications.
Dr. Kim is a graduate of the University of Hawaii with high honors in History and highest honors in Biology, received his M.D. from the Yale University School of Medicine, and trained in Internal Medicine and Infectious Diseases at Duke University Medical Center.
Dr. Kim has received numerous awards: John Maher Award for Research Excellence, Uniformed Services University (2013); Department of the Army Research and Development Achievement Award for Technical Excellence (2013); Asia Pacific Vaccine Excellence Lifetime Achievement Award (2021); Medal of Honor for Civil Merit from the Government of the Republic of Korea (2022).